Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-06-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
监事会关于公司2024年限制性股票激励计划激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board of a company regarding the list of incentive recipients under a 2024 restricted stock incentive plan. It includes details about the announcement, verification of the incentive recipients, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory announcement related to corporate governance and compliance with stock incentive regulations. Given the nature of the content and the absence of financial data or report format, this fits best under Regulatory Filings (RNS). The document length is short (1590 characters), and it is not an announcement of a report publication but a standalone announcement of supervisory board verification and disclosure.
2024-06-07 Chinese
第二届董事会审计委员会关于启动选聘2024年度审计机构工作的提议
Audit Report / Information Classification · 90% confidence The document is a proposal from the Audit Committee of the Board of Directors regarding the initiation of the selection process for the 2024 audit firm. It references regulatory guidelines and internal company policies related to the appointment of auditors. The document does not contain any financial statements or audit results but is an announcement about starting the audit firm selection process. It is not an audit report itself, nor an annual or interim report. Given the content and length, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full audit report or financial statement. Confidence is high due to clear references to audit firm selection and regulatory compliance. FY 2024
2024-06-06 Chinese
2024年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年第二次临时股东大会会议资料" which translates to "2024 Second Extraordinary General Meeting (EGM) Meeting Materials." It contains detailed meeting instructions, agenda, and proposals for shareholder approval, including stock incentive plans and authorization for the board to handle related matters. The content is clearly materials prepared for a shareholders' meeting, including meeting rules, agenda, and proposals to be voted on. There is no financial data or earnings information, nor is it a transcript or announcement of voting results. It is not a report publication announcement since the document itself contains the meeting materials, not just a notice of availability. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings).
2024-06-06 Chinese
关于开立理财产品专用结算账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company 科兴生物制药股份有限公司 regarding the opening of a dedicated settlement account for managing idle raised funds through financial products. It references regulatory guidelines on the management and use of raised funds and details the bank account information and risk control measures. The document is relatively short (1381 characters) and does not contain financial statements or detailed financial data. It is an update on the company's capital management activities, specifically about the use of idle raised funds for cash management. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2024-06-06 Chinese
2024年限制性股票激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan titled '2024年限制性股票激励计划 (草案)' which translates to '2024 Restricted Stock Incentive Plan (Draft)' for 科兴生物制药股份有限公司 (Sinovac Biotech Co., Ltd.). It extensively discusses the issuance of restricted stock to employees and management, including the number of shares, eligibility, grant price, vesting conditions, management structure, and legal compliance. The content focuses on the company's stock incentive plan, which is a capital/financing related update about share issuance and employee stock incentives. It is not a financial report, audit, earnings release, or management discussion. It is also not a simple announcement or regulatory filing but a substantive document outlining a stock incentive plan. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement or summary.
2024-05-24 Chinese
第二届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 15th meeting of the 2nd Board of Directors of 科兴生物制药股份有限公司 (Kexing Biopharmaceutical Co., Ltd.) held on May 24, 2024. It details the approval of a 2024 restricted stock incentive plan draft, its implementation assessment methods, and authorization requests for the board to handle related matters. It also announces the scheduling of a 2024 second extraordinary general meeting. The document is a board meeting resolution announcement, focusing on board decisions and governance matters, not a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement but a board/management information disclosure about board resolutions and governance actions. The document length is about 3,070 characters, consistent with a detailed board meeting announcement rather than a full report. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-05-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.